NICE nod for Takeda’s Adcetris in advanced stage CTCL
Takeda has announced the NICE recommendation of Adcetris for advanced cutaneous T-cell lymphoma.
Read More
Tag: CTCL
EC OKs Adcetris for CD30-positive cutaneous T-cell lymphoma
The European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy.
Read More
EU advisors back expanding use of Adcetris
Takeda’s Adcetris could soon be on the market in Europe as a second-line treatment for adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after regulatory advisors backed expanding the drug’s scope.
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
